Zacks Investment Research upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a sell rating to a hold rating in a research report report published on Wednesday morning.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Separately, Noble Financial reaffirmed a buy rating and set a $17.50 price target on shares of TherapeuticsMD in a research report on Monday, July 11th.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down 0.702% during mid-day trading on Wednesday, reaching $6.365. The company’s stock had a trading volume of 103,190 shares. TherapeuticsMD has a one year low of $5.18 and a one year high of $11.26. The stock has a 50 day moving average of $6.71 and a 200-day moving average of $7.67. The stock’s market cap is $1.25 billion.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The firm had revenue of $4.40 million for the quarter, compared to analysts’ expectations of $5.63 million. The business’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. On average, equities research analysts expect that TherapeuticsMD will post ($0.43) EPS for the current fiscal year.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.